TY - JOUR
T1 - Psychometrics of the self-report concise associated symptoms tracking scale (CAST-SR)
T2 - Results from the STRIDE (CTN-0037) study
AU - Trombello, Joseph M.
AU - Killian, Michael O.
AU - Liao, Allen
AU - Sanchez, Katherine
AU - Greer, Tracy L.
AU - Walker, Robrina
AU - Grannemann, Bruce
AU - Rethorst, Chad D.
AU - Carmody, Thomas
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Submitted: May 17, 2017; accepted December 6, 2017. Published online: January 9, 2018. Potential conflicts of interest: Dr Trombello owns stocks in Merck and Gilead Sciences. Dr Greer has received research funding from NARSAD and has received honoraria and consulting fees from H. Lundbeck A/S and Takeda. Dr Rethorst has received research funding from the National Institute of Mental Health, the American Cancer Society, and the Cancer Prevention Research Institute of Texas. Dr Trivedi is or has been an advisor/consultant and received fee from (lifetime disclosure) Abbott, Akzo (Organon), Allergan Sales, Alkermes, Arcadia, AstraZeneca, Axon Advisors, Brintellix, Bristol-Myers Squibb received grants/research support from Agency Company, Cephalon, Cerecor, Eli Lilly, Evotec, for Healthcare Research and Quality, Cyberonics, Fabre Kramer, Forest, GlaxoSmithKline, Global National Alliance for Research in Schizophrenia and Medical Education Inc., Health Research Associates, Depression, National Institute of Mental Health, Johnson & Johnson, Lundbeck, MedAvante National Institute on Drug Abuse, National Institute Medscape, Medtronic, Merck, Mitsubishi Tanabe of Diabetes and Digestive and Kidney Diseases, Pharma Development America, MSI Methylation and Johnson & Johnson; and receives royalties Sciences, Nestle Health Science–PamLab, Naurex, from Janssen. Drs Killian, Sanchez, Walker, and Neuronetics, One Carbon Therapeutics, Otsuka, Carmody and Messrs Liao and Grannemann Pamlab, Parke-Davis, Pfizer, PgxHealth, Phoenix report no conflicts of interest. Marketing Solutions, Rexahn, Ridge Diagnostics, Funding/support: Research reported in this Roche Products, Sepracor, Shire Development, publication was supported by the National Sierra, SK Life and Science, Sunovion, Takeda, Tal Institute on Drug Abuse of the National Institutes Medical/Puretech Venture, Targacept, Transcept, of Health under Award Numbers U10DA020024 and VantagePoint, Vivus, and Wyeth-Ayerst; has UG1DA020024 (principal investigator: Dr Trivedi).
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objective: The self-report Concise Associated Symptoms Tracking Scale (CAST-SR) was developed to track mania, irritability, anxiety, panic, and insomnia symptoms among depressed outpatients receiving antidepressant medication. Given the overlap between these domains, depression, and stimulant use disorders, we reexamined CAST-SR psychometrics in a novel sample: individuals with stimulant use disorder receiving aerobic exercise or health education interventions. Methods: Using the subsample of stimulant-dependent (following DSM-IV criteria) individuals prescribed antidepressants (N = 124) from the multisite Stimulant Reduction Intervention Using Dosed Exercise (CTN-0037) trial (total sample N = 302), conducted July 2010 to February 2013, we analyzed CAST-SR data collected at the first assessment after participant's discharge from residential treatment. We also evaluated the convergent/discriminant validity of the CAST-SR with several self-report questionnaires. Results: Confirmatory factor analysis revealed a 12-item measure composed of 4 factors: irritability, anxiety, panic, and insomnia. This factor structure loaded only in participants prescribed antidepressant medication, not in those who were not prescribed antidepressants. These results replicate the original CAST-SR factor structure, except for the mania factor, which failed to load. Internal consistency was high (a = 0.92 for total scale and a = 0.78-0.89 for the 4 factors), and convergent validity was established, especially for the insomnia and irritability factors, alongside the total score with depressive symptoms, insomnia, quality of life, suicide risk, and physical health measures. Conclusions: These results demonstrate the factor structure, reliability, and validity of the CAST-SR in a novel population of only individuals with stimulant use disorders receiving both exercise/health education interventions and antidepressant medication.
AB - Objective: The self-report Concise Associated Symptoms Tracking Scale (CAST-SR) was developed to track mania, irritability, anxiety, panic, and insomnia symptoms among depressed outpatients receiving antidepressant medication. Given the overlap between these domains, depression, and stimulant use disorders, we reexamined CAST-SR psychometrics in a novel sample: individuals with stimulant use disorder receiving aerobic exercise or health education interventions. Methods: Using the subsample of stimulant-dependent (following DSM-IV criteria) individuals prescribed antidepressants (N = 124) from the multisite Stimulant Reduction Intervention Using Dosed Exercise (CTN-0037) trial (total sample N = 302), conducted July 2010 to February 2013, we analyzed CAST-SR data collected at the first assessment after participant's discharge from residential treatment. We also evaluated the convergent/discriminant validity of the CAST-SR with several self-report questionnaires. Results: Confirmatory factor analysis revealed a 12-item measure composed of 4 factors: irritability, anxiety, panic, and insomnia. This factor structure loaded only in participants prescribed antidepressant medication, not in those who were not prescribed antidepressants. These results replicate the original CAST-SR factor structure, except for the mania factor, which failed to load. Internal consistency was high (a = 0.92 for total scale and a = 0.78-0.89 for the 4 factors), and convergent validity was established, especially for the insomnia and irritability factors, alongside the total score with depressive symptoms, insomnia, quality of life, suicide risk, and physical health measures. Conclusions: These results demonstrate the factor structure, reliability, and validity of the CAST-SR in a novel population of only individuals with stimulant use disorders receiving both exercise/health education interventions and antidepressant medication.
UR - http://www.scopus.com/inward/record.url?scp=85046901332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046901332&partnerID=8YFLogxK
U2 - 10.4088/JCP.17m11707
DO - 10.4088/JCP.17m11707
M3 - Article
C2 - 29325238
AN - SCOPUS:85046901332
VL - 79
SP - 41
EP - 47
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
SN - 0160-6689
IS - 2
ER -